|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500097996 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-28 09:51:04 |
|
注册时间: Date of Registration: |
2025-02-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
老年重症出血伴凝血异常患者目标导向管理策略:一项全国、多中心、前瞻性队列研究 |
|
Public title: |
Management Strategies For Bleeding Critically Ill Patients with Coagulopathy A Nationwide, Multicenter, Prospective Cohort Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
老年重症出血伴凝血异常患者目标导向管理策略:一项全国、多中心、前瞻性队列研究 |
|
Scientific title: |
Management Strategies For Bleeding Critically Ill Patients with Coagulopathy A Nationwide, Multicenter, Prospective Cohort Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
常志刚 |
研究负责人: |
常志刚 |
|
Applicant: |
Zhigang Chang |
Study leader: |
Zhigang Chang |
|
申请注册联系人电话: Applicant telephone: |
+86 137 1899 6970 |
研究负责人电话:
Study leader's |
+86 137 1899 6970 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhigangchang@126.com |
研究负责人电子邮件: Study leader's E-mail: |
zhigangchang@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市东城区东单大华路1号 |
研究负责人通讯地址: |
北京市东城区东单大华路1号 |
|
Applicant address: |
No.1, Dahua Road, Dongcheng District, Beijing. |
Study leader's address: |
No.1, Dahua Road, Dongcheng District, Beijing. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京医院 |
||
|
Applicant's institution: |
Beijing Hospital |
||
|
研究负责人所在单位: |
北京医院 |
||
|
Affiliation of the Leader: |
Beijing Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024BJYYEC-KY192-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京医院伦理委员会 |
||
|
Name of the ethic committee: |
Beijing Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-01 00:00:00 | ||
|
伦理委员会联系人: |
张弼 |
||
|
Contact Name of the ethic committee: |
Bi Zhang |
||
|
伦理委员会联系地址: |
北京市东城区东单大华路1号 |
||
|
Contact Address of the ethic committee: |
No.1, Dahua Road, Dongcheng District, Beijing. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 85138105 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市东城区东单大华路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.1, Dahua Road, Dongdan, Dongcheng District, Beijing,China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京医院队列专项 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Hospital Cohort special fund |
||||||||||||||||||||||
|
研究疾病: |
重症出血伴凝血异常 |
||||||||||||||||||||||
|
Target disease: |
Severe bleeding with abnormal coagulation |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
了解当前成人及老年重症出血伴凝血异常患者的临床实践情况,确定成人及老年重症出血患者的“目标导向性凝血管理策略”最优指标及范围;评价目标导向性凝血管理策略在成人及老年患者中的应用价值;探索老年重症出血患者的“目标导向性凝血管理策略”最佳治疗策略并明确其安全性。针对中国人群包括老年人群出血时的最佳治疗策略及其安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To understand the current clinical practice of adults and elderly patients with severe hemorrhage with abnormal coagulation, and determine the optimal index and scope of "goal-oriented coagulation management strategy" for adults and elderly patients with severe hemorrhage; To evaluate the application value of goal-oriented coagulation management strategy in adult and elderly patients; To explore the optimal treatment strategy of "goal-oriented coagulation management strategy" in elderly patients with severe bleeding and to clarify its safety. Optimal treatment strategy and safety for bleeding in Chinese population including elderly population. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、已签署知情同意书; 2、年满18周岁; 3、预计住ICU>24小时; 4、发生出血事件*(24小时内); 5、存在凝血异常*(低纤维蛋白原或者符合凝血病诊断)。 注1:出血事件*:临床存在出血事件,在没有其他情况下,患者满足以下标准之一: 1、外科出血,术中输注超过2U单位的RBC或者全血,或者术后Hb下降超过 2g/L; 2、非手术出血,需要输注超过2U的RBC或者全血;Hb下降超过 2g/L; 3、出血在关键部位或者关键器官*的症状性出血; 4、出血事件需要有创干预; 5、出血导致低血容量性休克(收缩压<90mmHg,或者下降>40mmHg); 6、出血导致伴有收缩压下降超过20mmHg或心率至少增加20次/min。 不符合这些标准的出血被定义为轻微出血,不纳入研究。 注2:凝血异常*(低纤维蛋白原或者符合凝血病诊断):满足以下标准之一: 1、出现低纤维蛋白血症:FIB(纤维蛋白原水平)<2.0g/L; 2、符合凝血病诊断标准:满足以下条件之一: 1、PT(部分凝血酶时间)>正常值1.5倍;或PT>16s;或INR>1.5; 2、APTT(活化部分凝血酶时间)>正常值1.5倍;或APTT>60s。 注3:关键部位*: 损害器官功能的出血被认为是关键部位*出血,例如颅内出血和其他中枢神经系统出血(如眼内出血、脊髓出血)。胸腔、气道、心包、腹腔内、腹膜后、关节内和肌肉内出血被认为是关键部位出血。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Signed informed consent 2.At least 18 years of age 3.Expected ICU stay >24 hours 4.Bleeding event * (within 24 hours) 5.There are coagulation abnormalities * (low fibrinogen or consistent with the diagnosis of coagulation disease). Note 1: Bleeding event * : There is clinical bleeding event, in the absence of other conditions, the patient meets one of the following criteria: 1.Surgical bleeding, intraoperative infusion of more than 2U units of RBC or whole blood, or postoperative Hb decline of more than 2g/L; 2.Non-surgical bleeding, requiring infusion of more than 2U RBC or whole blood; Hb decreased by more than 2g/L; 3.Symptomatic bleeding in key areas or key organs *; 4.Bleeding events require invasive intervention; 5.Haemorrhage leading to hypovolemic shock (systolic blood pressure <90mmHg, or drop >40mmHg); 6.Bleeding leads to a decrease in systolic blood pressure of more than 20mmHg or an increase in heart rate of at least 20 beats /min. Bleeding that did not meet these criteria was defined as minor bleeding and was not included in the study. Note 2: Abnormal coagulation * (low fibrinogen or meeting the diagnosis of coagulopathy) : one of the following criteria is met: 1.Low fibrinemia occurs: FIB(fibrinogen level) <2.0g/L; 2.Meet the diagnostic criteria for coagulation disease: meet one of the following conditions: 1.PT (partial thrombin time) > 1.5 times the normal value; Or PT>16s; Or INR>1.5; 2.APTT (activated partial thrombin time) > 1.5 times the normal value; Or APTT>60s. Note 3: Critical site * : Bleeding that impairs organ function is considered critical site * bleeding, such as intracranial bleeding and other central nervous system bleeding (e.g., intraocular bleeding, spinal cord bleeding). Thoracic, airway, pericardium, intraperitoneal, retroperitoneal, intra-articular and intramuscular bleeding are considered to be critical site bleeding. |
||||||||||||||||||||||
|
排除标准: |
1、接受姑息治疗或预计48h内死亡的患者; 2、孕妇或哺乳期妇女; 3、任何已知的先天性凝血障碍; 4、不符合出血事件的定义; 5、既不符合低纤维蛋白原血症,又不符合凝血病的诊断标准。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients receiving palliative care or expected to die within 48 hours; 2. Pregnant or lactating women; 3. any known congenital coagulation disorder; 4. does not meet the definition of bleeding events; 5. It does not meet the diagnostic criteria of hypofibrinogenemia and coagulation disease. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-03-07 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2027年12月后,EDC:医数据MedBit https://www.medbit.cn/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After December 2027, EDC: MedBit https://www.medbit.cn/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例报告表和电子病例报告表 EDC:医数据MedBit https://www.medbit.cn/ |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Report Form and Electronic Case Report Form EDC:MedBit https://www.medbit.cn/ |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |